Patents Examined by Louise Humphrey
  • Patent number: 9701954
    Abstract: The invention relates to a method for subjecting adherent cells to at least one electric field, in which the electric field is generated by applying a voltage to at least two active electrodes 63, wherein at least three electrodes 63, 64 are provided, and wherein at least two electrodes 63, 64 are active electrodes 63 when the voltage is applied in order to generate a first electric field, and in which at least one second electric field is generated, wherein at least one of the two previously active electrodes 63 is a potential-free electrode 64 when the voltage is applied.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: July 11, 2017
    Assignee: LONZA COLOGNE GMBH
    Inventors: Thomas Koblizek, Andreas Heinze, Timo Gleissner, Herbert Mueller-Hartmann, Andreas Wirth
  • Patent number: 9610346
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: March 10, 2013
    Date of Patent: April 4, 2017
    Assignee: International AIDS Vaccine Initiative
    Inventors: Svetlana Rabinovich, Maoli Yuan, Aaron J. Wilson, Sanjay Phogat, Ross W. B. Lindsay, Maria J. Chiuchiolo, Christopher L. Parks
  • Patent number: 9474793
    Abstract: The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: October 25, 2016
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Andrew Catanzaro, Robert Yarchoan, Jay A. Berzofsky, Takahiro Okazaki, James T. Snyder, II, Samuel Broder
  • Patent number: 9101579
    Abstract: Provided herein are methods of treating cancer in a cancer patient by overcoming resistance of a cancer cell to a drug, or methods of overcoming resistance of a cancer cell to a drug, comprising administering to the patient an effective amount of (i) an EGFR tyrosine kinase inhibitor or a B-Raf kinase inhibitor, and (ii) an HDAC inhibitor. Also provided are methods for inhibiting or preventing proliferation of drug tolerant persister (DTP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. Yet also provided are methods for inhibiting or preventing formation of colonies of drug tolerant expanded persister (DTEP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: August 11, 2015
    Assignee: Celgene Corporation
    Inventors: Aaron N. Nguyen, Kyle J. MacBeth, Jorge DiMartino
  • Patent number: 9079968
    Abstract: A motif is searched which can inhibit the proteolysis of a protein that has been administered to a cell or an individual. Thus, disclosed is a method for designing/producing a protein having resistance to proteolysis. Specifically disclosed is a motif capable of inhibiting proteolysis, which comprises an amino acid region lying between the 396th position and the 410th position from the C-terminal of DP-1.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: July 14, 2015
    Assignee: NIHON UNIVERSITY
    Inventors: Shigemasa Hanazawa, Yoshikazu Masuhiro
  • Patent number: 9079962
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 14, 2015
    Assignee: TRIPEP AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • Patent number: 9079950
    Abstract: A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: July 14, 2015
    Assignee: The Macfarlane Burnet Institute for Medical Research and Public Health Ltd
    Inventors: Heidi Drummer, Kathleen McCaffrey, Pantelis Poumbourios
  • Patent number: 9075059
    Abstract: The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (?AKTLLPTPGGS(PEG5000))4 KKKKDOTA?A-NH2, to which imaging agents and/or therapeutic agents can be conjugated.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: July 7, 2015
    Assignee: University of Virginia Patent Foundation
    Inventor: Kimberly A. Kelly
  • Patent number: 9061003
    Abstract: A collagen peptide mixture containing three or more kinds selected from Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, chemically-modified substances thereof and pharmaceutically acceptable salts thereof, and at least one peptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, Ser-Hyp-Gly, Gly-Pro-Hyp, (Pro-Hyp-Gly)5, Pro-Hyp, Hyp-Gly, Pro-Gly, Pro-Pro and Ala-Hyp or a chemically-modified substance thereof or a pharmaceutically acceptable salt thereof have DPPTV inhibitory activity and/or GLP-1 secretion accelerating activity, and hence are effective as a therapeutic or preventive agent or the like for diabetes.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: June 23, 2015
    Assignee: NITTA GELATIN INC.
    Inventors: Fumihito Sugihara, Naoki Inoue, Seiko Koizumi, Tadashi Yoshimoto, Hiroshi Oyama
  • Patent number: 9050286
    Abstract: The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of inter alia conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds utilized are represented by the general formula (I), as further defined in the specification.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: June 9, 2015
    Assignee: Ferring B.V.
    Inventors: Regent Laporte, Pierre J-M Riviere
  • Patent number: 9044420
    Abstract: Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: June 2, 2015
    Assignee: IMMUNE DESIGN CORP.
    Inventors: Thomas W. Dubensky, Jr., Scott H. Robbins
  • Patent number: 9028423
    Abstract: Methods and apparatus are disclosed for determining the occurrence of a closed or open apnea. Respiratory air flow from a patient is measured to give an air flow signal. The determination of an apnea is performed by applying an oscillatory pressure waveform of known frequency to a patient's airway, calculating a complex quantity representing a patient admittance (12) and comparing its value with ranges (14,16) indicative of open or closed apneas. The method distinguishes open from closed apneas even when the model used to calculate admittance is not based on details of the respiratory apparatus. In addition the patient admittance may be compared with admittance during normal breathing to avoid having to characterize the airway.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: May 12, 2015
    Assignee: ResMed Limited
    Inventors: David John Bassin, Benriah Goeldi
  • Patent number: 9029315
    Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In addition, the subject invention can be used in the prevention and/or treatment of tumor or cancer.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The University of Hong Kong
    Inventors: Zhiwei Chen, Jingying Zhou
  • Patent number: 9012214
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, the recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against the RNA virus or against both measles virus and against the RNA virus. It also relates to the use of the recombinant measles virus for the preparation of immunogenic compositions.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: April 21, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Clarisse Lorin, Lucile Mollet, Frédéric Delebecque
  • Patent number: 9005624
    Abstract: Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: April 14, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Alexander Berthold Hendrik Bakker, Willem Egbert Marissen, Robert Arjen Kramer, Cornelis Adriaan De Kruif
  • Patent number: 9005961
    Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain, for example, the Schwarz strain. It also concerns the preparation of infectious recombinant viruses and immunogenic compositions using the cDNA.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: April 14, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Fréderic Tangy, Chantal Combredet, Valérie Labrousse-Najburg, Michel Brahic
  • Patent number: 9006420
    Abstract: A simple and convenient method for concentrating a biomolecule, including protein or nucleic acid molecules, from a sample. Purified and isolated biomolecules obtained by this method. Methods for improving the specificity or sensitivity of detecting a biomolecule by concentration and/or purification or isolation of the biomolecule according to the method of the invention.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: April 14, 2015
    Inventor: Timo Hillebrand
  • Patent number: 9005925
    Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: April 14, 2015
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Frédéric Tangy, Chantal Combredet, Valérie Labrousse-Najburg, Michel Brahic
  • Patent number: 9000139
    Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: April 7, 2015
    Assignee: Genexine, Inc.
    Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
  • Patent number: 8999927
    Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 7, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Qing-Rong Liu